<DOC>
	<DOCNO>NCT02633839</DOCNO>
	<brief_summary>This open label , parallel group study evaluate pharmacokinetics ( PK ) safety single dose CVT-301 smoking non-smoking adult .</brief_summary>
	<brief_title>A Study Safety Levodopa Pharmacokinetics Following Single Dose Administration CVT 301 ( Levodopa Inhalation Powder ) Smoking Non-Smoking Adults</brief_title>
	<detailed_description />
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Body mass index ( BMI ) 18 32 kg/m2 ; Forced expiratory volume one second ( FEV1 ) ≥80 % predict race , age , sex , height ; FEV1/FVC ( force vital capacity ) ratio ≥70 % ; Smokers define currently smoke least 10 cigarettes/day least 12 month positive urinary cotinine result past ( within 5 year ) present history intrinsic lung disease ( e.g . asthma , chronic obstructive pulmonary disease [ COPD ] , chronic bronchitis , relevant condition ) ; Nonsmokers define never smoke expose less 1 pack year within least 12 month negative urinary cotinine result . Subject surgically sterile female subject le 2 year postmenopausal , agree use highly effective birth control method study 3 month last dose investigational product ; Any flulike syndrome respiratory infection within 2 week prior Screening Visit ; History chronic obstructive pulmonary disorder ( COPD ) require intermittent continuous use oral inhaled medication therapy within last 3 year ; Renal impairment define calculated creatinine clearance ≤ 80 mL/minute ; History syncope within last 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Adults</keyword>
</DOC>